Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122359
Filing Date
2024-11-06
Accepted
2024-11-06 16:20:57
Documents
62
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tnya-20240930.htm   iXBRL 10-Q 2096978
2 EX-4.1 tnya-ex4_1.htm EX-4.1 184613
3 EX-10.1 tnya-ex10_1.htm EX-10.1 712279
4 EX-31.1 tnya-ex31_1.htm EX-31.1 21162
5 EX-32.1 tnya-ex32_1.htm EX-32.1 8948
  Complete submission text file 0000950170-24-122359.txt   8239184

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20240930.xsd EX-101.SCH 992747
65 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20240930_htm.xml XML 1052855
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40656 | Film No.: 241431345
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)